ArticleMedical journal of the Islamic Republic of Iran2025
Non-Randomized Controlled Trial Comparing Response of Rectal Cancer Chemoradiation with and without Low-Dose Aspirin.
Article in Medical journal of the Islamic Republic of Iran, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer poses a significant global health challenge, with high incidence and mortality rates. Neoadjuvant chemoradiotherapy (CRT) is standard for rectal adenocarcinoma to improve surgical outcomes and reduce recurrence, yet the overall treatment efficacy remains inadequate. This study investigates the effects of low-dose aspirin as an adjunct therapy during neoadjuvant CRT in rectal cancer patients. Methods: This non-randomized controlled trial included 90 patients with histologically confirmed Stage II or III rectal adenocarcinoma, allocated into two arms (45 each) receiving standard neoadjuvant CRT with or without 100 mg of daily oral aspirin. Primary outcomes included pathological complete response (pCR) rates, while secondary outcomes encompassed tumor regression grade (TRG) and tumor down-staging. Safety was assessed by monitoring aspirin-related adverse events. Comparisons between groups for the primary outcome and secondary outcomes were performed using chi-square tests. Results: The aspirin group exhibited a significantly higher pCR rate of 26.6% compared to 17.7% in the control group ( Conclusion: Low-dose aspirin enhances the efficacy of neoadjuvant chemoradiation in rectal cancer patients, leading to improved pCR and tumor down-staging with minimal toxicity. These findings support aspirin's potential as a cost-effective adjunct to standard treatment protocols, warranting further investigation in larger trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.